(PharmaNewsWire.Com, June 24, 2017 ) This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
- The report provides a snapshot of the global therapeutic landscape of Women Infertility - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Women Infertility - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Company profiles
AbbVie Inc. Actavis plc Addex Therapeutics Ltd AlphaMab Co., Ltd APAvadis Biotechnologies Srl ASKA Pharmaceutical Co., Ltd. Astellas Pharma Inc. AstraZeneca PLC Bayer AG Crinetics Pharmaceuticals, Inc. Dong-A Socio Group Dongkook Pharmaceutical Co., Ltd. EffRx Pharmaceuticals S.A. ElexoPharm GmbH EndoCeutics, Inc. Euroscreen S.A. Evotec AG Ferring International Center S.A. Finox AG Forendo Pharma Oy GlaxoSmithKline plc Glycotope GmbH Isifer AB Kissei Pharmaceutical Co., Ltd. Lipicard Technologies Limited Merck & Co., Inc. Merck KGaA Neurocrine Biosciences, Inc. Nora Therapeutics, Inc. ObsEva SA Orphagen Pharmaceuticals, Inc. Pantec Biosolutions AG PharmaEssentia Corporation Philogen S.p.A. PlasmaTech Biopharmaceuticals, Inc. PregLem SA Reliance Life Sciences Pvt. Ltd. Repros Therapeutics Inc. SK Chemicals Co., Ltd. Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Trophogen, Inc. ValiRx Plc Zydus Cadila Healthcare Limited
Number of Products under Development for Women Infertility, H1 2015 17 Number of Products under Development for Women Infertility-Comparative Analysis, H1 2015 18 Number of Products under Development by Companies, H1 2015 20 Number of Products under Development by Companies, H1 2015 (Contd..1) 21 Number of Products under Development by Companies, H1 2015 (Contd..2) 22 Number of Products under Development by Companies, H1 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2015 25 Comparative Analysis by Late Stage Development, H1 2015 26 Comparative Analysis by Clinical Stage Development, H1 2015 27 Comparative Analysis by Early Stage Development, H1 2015 28 Comparative Analysis by Unknown Stage Development, H1 2015 29 Products under Development by Companies, H1 2015 30 Products under Development by Companies, H1 2015 (Contd..1) 31 Products under Development by Companies, H1 2015 (Contd..2) 32 Products under Development by Companies, H1 2015 (Contd..3) 33 Products under Development by Companies, H1 2015 (Contd..4) 34 Products under Investigation by Universities/Institutes, H1 2015 35 Women Infertility-Pipeline by AbbVie Inc., H1 2015 36 Women Infertility-Pipeline by Actavis plc, H1 2015 37 Women Infertility-Pipeline by Addex Therapeutics Ltd, H1 2015 38 Women Infertility-Pipeline by AlphaMab Co., Ltd, H1 2015 39 Women Infertility-Pipeline by APAvadis Biotechnologies Srl, H1 2015 40 Women Infertility-Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2015 41 Women Infertility-Pipeline by Astellas Pharma Inc., H1 2015 42 Women Infertility-Pipeline by AstraZeneca PLC, H1 2015 43 Women Infertility-Pipeline by Bayer AG, H1 2015 44 Women Infertility-Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 45 Women Infertility-Pipeline by Dong-A Socio Group, H1 2015 46 Women Infertility-Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 47 Women Infertility-Pipeline by EffRx Pharmaceuticals S.A., H1 2015 48 Women Infertility-Pipeline by ElexoPharm GmbH, H1 2015 49 Women Infertility-Pipeline by EndoCeutics, Inc., H1 2015 50 Women Infertility-Pipeline by Euroscreen S.A., H1 2015 51 Women Infertility-Pipeline by Evotec AG, H1 2015 52 Women Infertility-Pipeline by Ferring International Center S.A., H1 2015 53 Women Infertility-Pipeline by Finox AG, H1 2015 54 Women Infertility-Pipeline by Forendo Pharma Oy, H1 2015 55 Women Infertility-Pipeline by GlaxoSmithKline plc, H1 2015 56 Women Infertility-Pipeline by Glycotope GmbH, H1 2015 57 Women Infertility-Pipeline by Isifer AB, H1 2015 58 Women Infertility-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 59 Women Infertility-Pipeline by Lipicard Technologies Limited, H1 2015 60 Women Infertility-Pipeline by Merck & Co., Inc., H1 2015 61 Women Infertility-Pipeline by Merck KGaA, H1 2015 62 Women Infertility-Pipeline by Neurocrine Biosciences, Inc., H1 2015 63 Women Infertility-Pipeline by Nora Therapeutics, Inc., H1 2015 64 Women Infertility-Pipeline by ObsEva SA, H1 2015 65 Women Infertility-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 66 Women Infertility-Pipeline by Pantec Biosolutions AG, H1 2015 67 Women Infertility-Pipeline by PharmaEssentia Corporation, H1 2015 68 Women Infertility-Pipeline by Philogen S.p.A., H1 2015 69 Women Infertility-Pipeline by PlasmaTech Biopharmaceuticals, Inc., H1 2015 70 Women Infertility-Pipeline by PregLem SA, H1 2015 71 Women Infertility-Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 72 Women Infertility-Pipeline by Repros Therapeutics Inc., H1 2015 73 Women Infertility-Pipeline by SK Chemicals Co., Ltd., H1 2015 74 Women Infertility-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 75 Women Infertility-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76 Women Infertility-Pipeline by Trophogen, Inc., H1 2015 77 Women Infertility-Pipeline by ValiRx Plc, H1 2015 78 Women Infertility-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 79 Assessment by Monotherapy Products, H1 2015 80 Assessment by Combination Products, H1 2015 81 Number of Products by Stage and Target, H1 2015 83 Number of Products by Stage and Mechanism of Action, H1 2015 86 Number of Products by Stage and Route of Administration, H1 2015 88 Number of Products by Stage and Molecule Type, H1 2015 90 Women Infertility Therapeutics-Recent Pipeline Updates, H1 2015 182 Women Infertility-Dormant Projects, H1 2015 201 Women Infertility-Dormant Projects (Contd..1), H1 2015 202 Women Infertility-Dormant Projects (Contd..2), H1 2015 203 Women Infertility-Dormant Projects (Contd..3), H1 2015 204 Women Infertility-Discontinued Products, H1 2015 205 Women Infertility-Discontinued Products (Contd..1), H1 2015 206
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
